Junhemeng is a research and development company of recombinant protein drugs. Junhemeng has built a druggable and innovative recombinant protein drug development platform, covering high-efficiency expression systems of recombinant proteins, unique micro-denaturation separation and purification technology, protein in vitro Folding and self-assembly systems, as well as long-term slow-release and other high-barrier technology reserves that have achieved industrialization. Recently, JunHemeng completed the A+ round of financing of nearly 100 million yuan. This round of financing was jointly invested by Bencao Capital and Spotlight Capital, and Kaicheng Capital continued to serve as the exclusive financial advisor. The funds raised in this round of financing will be mainly used to further promote the development of the company’s product pipeline under research, expand the reserve pipeline and build a GMP commercial production base.
This article is transferred from: https://www.itjuzi.com/investevent/13776196
This site is only for collection, and the copyright belongs to the original author.